Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target

• Published in: American journal of ophthalmology Vol. 186; pp. 152 - 163
• Main Authors: Roybal, C. Nathaniel, Velez, Gabriel, Toral, Marcus A., Tsang, Stephen H., Bassuk, Alexander G., Mahajan, Vinit B.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2018; Elsevier Limited
• Subjects: Biopsy; Case-Control Studies; Cytokines; Cytokines - biosynthesis; Datasets; Diabetic retinopathy; Disease; Female; Follow-Up Studies; Humans; Inflammation; Male; Membranes; Ophthalmology; Prospective Studies; Proteins; Proteomics; Proteomics - methods; Retina; TOR Serine-Threonine Kinases - biosynthesis; Variance analysis; Vitrectomy; Vitreoretinopathy, Proliferative - metabolism; Vitreoretinopathy, Proliferative - pathology; Vitreoretinopathy, Proliferative - surgery; Vitreous Body - metabolism; Vitreous Body - pathology; Vitreous Body - surgery; United States > US
• ISSN: 0002-9394; 1879-1891; 1879-1891
• DOI: 10.1016/j.ajo.2017.11.025

To profile vitreous cytokine expression of proliferative vitreoretinopathy (PVR) patients. Case-control study. Liquid biopsies were collected from 2 groups: control subjects (n = 3) undergoing pars plana vitrectomy to remove an epiretinal membrane (ERM), and test subjects (n = 7) with varying degrees of PVR. A high-throughput cytokine screen measured expression of 200 cytokines. Cytokine expression patterns were prospectively validated in separate cohorts of control patients and those with PVR-A, PVR-B, and PVR-C (n = 10 for each group). Expression changes were evaluated by analysis of variance (significant P value < .05), hierarchical cluster algorithm, and pathway analysis, to identify candidate pathways for prospective studies. In PVR vitreous, 29 cytokines were upregulated compared to controls. Early PVR vitreous showed upregulation of T-cell markers, profibrotic cytokines, and cytokines downstream of mTOR activation (IL-2, IL-6, and IL-13), whereas in late PVR vitreous, cytokines driving monocyte responses and stem-cell recruitment (SDF-1) prevailed. Prospective validation confirmed the differential expression of specific cytokines from PVR-A to C. Early PVR is characterized by activation of T cells and mTOR signaling, whereas advanced PVR is characterized by a chronic monocyte response. PVR might be treated by rational repositioning of existing drugs that target mTOR and IL-6. Our analysis demonstrates that successful therapeutic intervention will be highly dependent on the specific therapeutic target and the stage of PVR. This study provides insights into cytokines that will serve as biomarkers and therapeutic targets. These biomarkers will help design clinical trials that intervene at appropriate times.